Paul Andrew Moore sold $316K of Zymeworks (ZYME)

Executed Jan 6 2025, disclosed Jan 6 2025, the same day.

Value, as filed

$316K

21,200 sh across 2 lots

Executed

Jan 6 2025

the trade date, as filed

Disclosed

Jan 6 2025

0 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

purchases only

Returns are measured on stock purchases only.

The filer

PM Paul Andrew Moore Chief Scientific Officer profile →

Paul Andrew Moore (Chief Scientific Officer) filed 2 Form 4 reports in the trailing twelve months (0 purchases, 2 sales), most often in Zymeworks Inc. (ZYME). The largest single filing was $505K of ZYME (20,110 sh across 2 lots, as filed), executed Jan 5.

The name

ZYME Zymeworks Inc. ZYME · Healthcare · 26 filings in 24 months ticker →

Healthcare · Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by Paul Andrew Moore in ZYME

ZYMESALE Zymeworks Inc. $217K
9,560 sh × $22.67
Exec Jan 12
Filed Jan 12 · 5:30 PM ET ZYMESALE Zymeworks Inc. $505K
20,110 sh across 2 lots
Exec Jan 5
Filed Jan 5 · 5:30 PM ET